Total Payments
$442.65
2022 Payments
$76.98
Companies
7
Transactions
28
Medicare Patients
10,842
Medicare Billing
$3.0M
Payment Breakdown by Category
Food & Beverage$442.65 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $442.65 | 28 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $171.65 | 10 | $0 (2021) |
| Genentech USA, Inc. | $157.82 | 10 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $39.78 | 3 | $0 (2019) |
| Alimera Sciences, Inc. | $29.39 | 2 | $0 (2017) |
| Alcon Laboratories Inc | $16.03 | 1 | $0 (2017) |
| Bausch & Lomb Americas Inc. | $14.96 | 1 | $0 (2022) |
| Mallinckrodt LLC | $13.02 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $76.98 | 5 | Genentech USA, Inc. ($62.02) |
| 2021 | $27.43 | 2 | Allergan, Inc. ($14.25) |
| 2020 | $12.21 | 1 | Allergan, Inc. ($12.21) |
| 2019 | $41.74 | 3 | Novartis Pharmaceuticals Corporation ($28.48) |
| 2018 | $87.84 | 5 | Genentech USA, Inc. ($52.27) |
| 2017 | $196.45 | 12 | Allergan Inc. ($96.36) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/17/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/26/2022 | Genentech USA, Inc. | SUSVIMO (Drug), VABYSMO | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/30/2022 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: Ophthalmology | ||||||
| 03/16/2022 | Genentech USA, Inc. | SUSVIMO (Drug), VABYSMO | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Immunology and Ophthalmology | ||||||
| 02/16/2022 | Genentech USA, Inc. | SUSVIMO (Drug), VABYSMO | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/17/2021 | Genentech USA, Inc. | SUSVIMO (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Immunology and Ophthalmology | ||||||
| 01/21/2021 | Allergan, Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: RETINA | ||||||
| 09/23/2020 | Allergan, Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $12.21 | General |
| Category: RETINA | ||||||
| 11/06/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/28/2019 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: RETINA | ||||||
| 06/05/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/15/2018 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $12.98 | General |
| Category: Ophthalmology | ||||||
| 06/12/2018 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: RETINA | ||||||
| 05/17/2018 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $22.45 | General |
| 05/02/2018 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: RETINA | ||||||
| 03/14/2018 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: Ophthalmology | ||||||
| 12/12/2017 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: RETINA | ||||||
| 11/15/2017 | Novartis Pharmaceuticals Corporation | DUREZOL (Drug) | Food and Beverage | In-kind items and services | $11.30 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/06/2017 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $36.16 | General |
| Category: RETINA | ||||||
| 10/25/2017 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: RETINA | ||||||
| 06/26/2017 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: RETINA | ||||||
| 06/07/2017 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Ophthalmology | ||||||
| 05/05/2017 | Alimera Sciences, Inc. | Iluvien (Biological) | Food and Beverage | Cash or cash equivalent | $13.75 | General |
| Category: Ophthalmology | ||||||
| 04/10/2017 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 04/05/2017 | Alimera Sciences, Inc. | Iluvien (Biological) | Food and Beverage | Cash or cash equivalent | $15.64 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 12 | 2,193 | 3,340 | $1.1M | $449,650 |
| 2021 | 18 | 4,448 | 8,761 | $3.1M | $1.3M |
| 2020 | 20 | 4,201 | 8,764 | $3.1M | $1.3M |
Total Patients
10,842
Total Services
20,865
Medicare Billing
$3.0M
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 148 | 408 | $612,000 | $294,225 | 48.1% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 28 | 168 | $109,200 | $39,118 | 35.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 432 | 649 | $105,787 | $32,218 | 30.5% |
| 92134 | Imaging of retina | Office | 2022 | 676 | 1,056 | $95,040 | $25,351 | 26.7% |
| 67028 | Injection of drug into eye | Office | 2022 | 205 | 316 | $76,472 | $22,805 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 244 | 244 | $56,364 | $15,303 | 27.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 88 | 88 | $30,096 | $7,466 | 24.8% |
| 92250 | Photography of the retina | Office | 2022 | 248 | 248 | $34,720 | $5,429 | 15.6% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 50 | 69 | $9,315 | $3,433 | 36.9% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 27 | 28 | $5,628 | $1,587 | 28.2% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 25 | 25 | $6,800 | $1,461 | 21.5% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2022 | 22 | 41 | $7,380 | $1,255 | 17.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 215 | 1,003 | $1.5M | $732,161 | 48.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2021 | 59 | 507 | $329,550 | $127,809 | 38.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 658 | 1,401 | $221,361 | $90,859 | 41.0% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 1,160 | 2,776 | $249,840 | $82,855 | 33.2% |
| 67028 | Injection of drug into eye | Office | 2021 | 311 | 802 | $178,950 | $66,117 | 36.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 536 | 588 | $133,572 | $48,583 | 36.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 280 | 280 | $95,760 | $33,111 | 34.6% |
| 92250 | Photography of the retina | Office | 2021 | 593 | 630 | $88,200 | $18,213 | 20.7% |
| 67036 | Removal of eye fluid (vitreous) between the lens and retina | Facility | 2021 | 22 | 23 | $44,551 | $15,689 | 35.2% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 161 | 166 | $45,152 | $14,984 | 33.2% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 179 | 191 | $36,711 | $12,889 | 35.1% |
| 67145 | Preventive retinal detachment treatment by heat or laser, 1 or more sessions | Office | 2021 | 25 | 30 | $34,170 | $12,582 | 36.8% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2021 | 121 | 177 | $23,895 | $9,716 | 40.7% |
About Dr. Thomas Grube, MD
Dr. Thomas Grube, MD is a Ophthalmology healthcare provider based in Mandan, North Dakota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659328516.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Grube, MD has received a total of $442.65 in payments from pharmaceutical and medical device companies, with $76.98 received in 2022. These payments were reported across 28 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($442.65).
As a Medicare-enrolled provider, Grube has provided services to 10,842 Medicare beneficiaries, totaling 20,865 services with total Medicare billing of $3.0M. Data is available for 3 years (2020–2022), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Surgery
- Location Mandan, ND
- Active Since 05/27/2006
- Last Updated 08/18/2010
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1659328516
Products in Payments
- OZURDEX (Drug) $171.65
- Lucentis (Biological) $60.17
- SUSVIMO (Drug) $57.99
- Iluvien (Biological) $29.39
- BEOVU (Drug) $28.48
- VABYSMO (Drug) $17.21
- Constellation (Device) $16.03
- XIPERE (Drug) $14.96
- ACTHAR (Biological) $13.02
- DUREZOL (Drug) $11.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.